Eli Lilly and Company (NYSE:LLY) Shares Bought by Lockerman Financial Group Inc.

Lockerman Financial Group Inc. lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 636 shares of the company’s stock after purchasing an additional 22 shares during the quarter. Lockerman Financial Group Inc.’s holdings in Eli Lilly and Company were worth $563,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in LLY. Scarborough Advisors LLC grew its position in shares of Eli Lilly and Company by 7.4% during the 4th quarter. Scarborough Advisors LLC now owns 465 shares of the company’s stock valued at $271,000 after acquiring an additional 32 shares during the period. Richardson Financial Services Inc. acquired a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $43,000. Warren Street Wealth Advisors LLC increased its position in shares of Eli Lilly and Company by 15.4% in the fourth quarter. Warren Street Wealth Advisors LLC now owns 964 shares of the company’s stock valued at $562,000 after buying an additional 129 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund raised its stake in shares of Eli Lilly and Company by 38.6% during the 4th quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 417,700 shares of the company’s stock worth $243,486,000 after buying an additional 116,300 shares during the period. Finally, Livelsberger Financial Advisory purchased a new position in shares of Eli Lilly and Company during the 4th quarter valued at approximately $135,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have issued reports on LLY. Citigroup assumed coverage on shares of Eli Lilly and Company in a report on Friday, September 13th. They set a “buy” rating and a $1,060.00 price objective on the stock. Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Truist Financial boosted their price target on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research report on Thursday, October 10th. Guggenheim upped their price objective on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Finally, Wells Fargo & Company increased their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a report on Friday, August 9th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $979.29.

Eli Lilly and Company Trading Down 1.7 %

NYSE LLY traded down $16.19 during trading on Tuesday, hitting $913.32. The stock had a trading volume of 2,268,359 shares, compared to its average volume of 2,998,500. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The company has a market capitalization of $868.02 billion, a PE ratio of 134.14, a PEG ratio of 2.79 and a beta of 0.42. The firm has a 50 day moving average price of $913.95 and a 200 day moving average price of $854.46. Eli Lilly and Company has a twelve month low of $547.61 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The firm had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, equities research analysts forecast that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.